Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1985 1
1986 1
1988 1
1989 2
1990 5
1991 2
1992 4
1993 1
1994 6
1995 6
1996 3
1997 2
1998 7
1999 10
2000 4
2001 14
2002 13
2003 15
2004 15
2005 11
2006 17
2007 14
2008 15
2009 16
2010 10
2011 20
2012 22
2013 11
2014 15
2015 11
2016 7
2017 12
2018 15
2019 13
2020 6
2021 7
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Results by year

Filters applied: . Clear all
Page 1
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Among authors: debiec rychter m. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P, Debiec-Rychter M. Rutkowski P, et al. Among authors: debiec rychter m. Expert Rev Anticancer Ther. 2015;15(8):901-9. doi: 10.1586/14737140.2015.1052799. Epub 2015 May 31. Expert Rev Anticancer Ther. 2015. PMID: 26027711 Review.
New targets and therapies for gastrointestinal stromal tumors.
Wozniak A, Gebreyohannes YK, Debiec-Rychter M, Schöffski P. Wozniak A, et al. Among authors: debiec rychter m. Expert Rev Anticancer Ther. 2017 Dec;17(12):1117-1129. doi: 10.1080/14737140.2017.1400386. Expert Rev Anticancer Ther. 2017. PMID: 29110548 Review.
GIST under imatinib therapy.
Sciot R, Debiec-Rychter M. Sciot R, et al. Among authors: debiec rychter m. Semin Diagn Pathol. 2006 May;23(2):84-90. doi: 10.1053/j.semdp.2006.08.005. Semin Diagn Pathol. 2006. PMID: 17193821 Review.
Clinical management of uterine sarcomas.
Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Amant F, et al. Among authors: debiec rychter m. Lancet Oncol. 2009 Dec;10(12):1188-98. doi: 10.1016/S1470-2045(09)70226-8. Lancet Oncol. 2009. PMID: 19959075 Review.
Guidelines for cytogenetic investigations in tumours.
Hastings RJ, Bown N, Tibiletti MG, Debiec-Rychter M, Vanni R, Espinet B, van Roy N, Roberts P, van den Berg-de-Ruiter E, Bernheim A, Schoumans J, Chatters S, Zemanova Z, Stevens-Kroef M, Simons A, Heim S, Salido M, Ylstra B, Betts DR; Tumour Best Practice meeting; Eurogentest. Hastings RJ, et al. Among authors: debiec rychter m. Eur J Hum Genet. 2016 Jan;24(1):6-13. doi: 10.1038/ejhg.2015.35. Epub 2015 Mar 25. Eur J Hum Genet. 2016. PMID: 25804401 Free PMC article. No abstract available.
PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.
Arts FA, Sciot R, Brichard B, Renard M, de Rocca Serra A, Dachy G, Noël LA, Velghe AI, Galant C, Debiec-Rychter M, Van Damme A, Vikkula M, Helaers R, Limaye N, Poirel HA, Demoulin JB. Arts FA, et al. Among authors: debiec rychter m. Hum Mol Genet. 2017 May 15;26(10):1801-1810. doi: 10.1093/hmg/ddx081. Hum Mol Genet. 2017. PMID: 28334876
318 results